HYPD
Price
$2.92
Change
-$0.18 (-5.81%)
Updated
Oct 22 closing price
Capitalization
45.38M
21 days until earnings call
Intraday BUY SELL Signals
NTRB
Price
$5.81
Change
-$0.33 (-5.37%)
Updated
Oct 22 closing price
Capitalization
70.62M
48 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

HYPD vs NTRB

HYPD vs NTRB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
HYPD vs. NTRB commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HYPD is a StrongBuy and NTRB is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for HYPD with price predictions
Oct 22, 2026

HYPD sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for HYPD moved above the 200-day moving average on October 19, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where HYPD's RSI Oscillator exited the oversold zone, 27 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +8.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where HYPD advanced for three days, in 187 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

HYPD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HYPD as a result. In 63 of 73 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

The Moving Average Convergence Divergence Histogram (MACD) for HYPD turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 36 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

HYPD moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for HYPD crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HYPD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for HYPD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.445) is normal, around the industry mean (2.973). P/E Ratio (-0.779) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (25.707) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. HYPD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HYPD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for NTRB with price predictions
Oct 22, 2026

NTRB's RSI Oscillator leaves overbought zone

The 10-day RSI Indicator for NTRB moved out of overbought territory on September 25, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In 21 of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTRB as a result. In 87 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

The Moving Average Convergence Divergence Histogram (MACD) for NTRB turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 38 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.

NTRB moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

NTRB broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 50-day moving average for NTRB moved above the 200-day moving average on September 17, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +3.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRB advanced for three days, in 197 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

The Aroon Indicator entered an Uptrend today. In 77 of 113 cases where NTRB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. NTRB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.261) is normal, around the industry mean (2.973). P/E Ratio (-11.857) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (52.632) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTRB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
HYPD vs NTRB: Fundamental Ratings
HYPD
NTRB
OUTLOOK RATING
1..100
7793
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9699
PRICE GROWTH RATING
1..100
6437
P/E GROWTH RATING
1..100
50100
SEASONALITY SCORE
1..100
90n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HYPD's Valuation (45) in the Pharmaceuticals Major industry is in the same range as NTRB (60) in the null industry. This means that HYPD’s stock grew similarly to NTRB’s over the last 12 months.

HYPD's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as NTRB (100) in the null industry. This means that HYPD’s stock grew similarly to NTRB’s over the last 12 months.

HYPD's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as NTRB (99) in the null industry. This means that HYPD’s stock grew similarly to NTRB’s over the last 12 months.

NTRB's Price Growth Rating (37) in the null industry is in the same range as HYPD (64) in the Pharmaceuticals Major industry. This means that NTRB’s stock grew similarly to HYPD’s over the last 12 months.

HYPD's P/E Growth Rating (50) in the Pharmaceuticals Major industry is somewhat better than the same rating for NTRB (100) in the null industry. This means that HYPD’s stock grew somewhat faster than NTRB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HYPDNTRB
RSI
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 24 days ago
80%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 3 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
68%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (HYPD: $3.10 vs. NTRB: $6.14)
Brand notoriety: HYPD and NTRB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HYPD: 30% vs. NTRB: 16%
Market capitalization -- HYPD: $45.38M vs. NTRB: $70.62M
HYPD [@Biotechnology] is valued at $45.38M. NTRB’s [@Biotechnology] market capitalization is $70.62M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HYPD’s FA Score shows that 0 FA rating(s) are green while NTRB’s FA Score has 0 green FA rating(s).

  • HYPD’s FA Score: 0 green, 5 red.
  • NTRB’s FA Score: 0 green, 5 red.
According to our system of comparison, HYPD is a better buy in the long-term than NTRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HYPD’s TA Score shows that 6 TA indicator(s) are bullish while NTRB’s TA Score has 5 bullish TA indicator(s).

  • HYPD’s TA Score: 6 bullish, 5 bearish.
  • NTRB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, HYPD is a better buy in the short-term than NTRB.

Price Growth

HYPD (@Biotechnology) experienced а +0.32% price change this week, while NTRB (@Biotechnology) price change was -2.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

HYPD is expected to report earnings on Nov 12, 2026.

NTRB is expected to report earnings on Dec 09, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
HYPD
Daily Signal:
Gain/Loss:
NTRB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

HYPD and

Correlation & Price change

A.I.dvisor indicates that over the last year, HYPD has been loosely correlated with KYNB. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if HYPD jumps, then KYNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HYPD
1D Price
Change %
HYPD100%
-5.81%
KYNB - HYPD
48%
Loosely correlated
-3.26%
LITS - HYPD
45%
Loosely correlated
-4.03%
ACXP - HYPD
36%
Loosely correlated
-0.87%
INKT - HYPD
34%
Loosely correlated
-5.27%
NKTR - HYPD
33%
Poorly correlated
+0.99%
More

NTRB and

Correlation & Price change

A.I.dvisor tells us that NTRB and VRAX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NTRB and VRAX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTRB
1D Price
Change %
NTRB100%
-5.37%
VRAX - NTRB
31%
Poorly correlated
-8.21%
DWTX - NTRB
28%
Poorly correlated
-4.27%
SYRE - NTRB
27%
Poorly correlated
-0.67%
JSPR - NTRB
27%
Poorly correlated
-1.73%
HYPD - NTRB
27%
Poorly correlated
-5.81%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
QQQD12.050.40
+3.39%
Direxion Daily Concentrated Qs Bear 1X Shares
MIY11.800.07
+0.60%
Blackrock Muniyield Michigan Quality Fund
CARY20.310.07
+0.37%
Angel Oak Income ETF (CARY)
ZSB20.59N/A
N/A
USCF Sustainable Battery Metals Strategy Fund (ZSB)
GSJY54.21-0.66
-1.20%
Goldman Sachs ActiveBeta Japan Equity ETF (GSJY)